LIBERATE

Midodrine for the early liberation from vasopressor support in the ICU

Volume 1/Issue 1

Welcome to the LIBERATE Study newsletter

The past year has been productive for the LIBERATE Study with 3 sites activated and recruiting and 2 sites slated for site activation in early 2023.

In addition, we've published protocol papers for the multi site RCT https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-022-06115-0 and for a systematic review https://bmjopen.bmj.com/content/12/11/e064060. We expect to publish the results of the systematic review in the next few weeks.

Finally, data collection for the Pilot Study has been completed and locked and an abstract has been submitted to ISICEM.

Thank you to all of the Study Site Teams and to the Steering Committee for your contributions in 2022. We extend our warmest wishes over the holiday season!

Frequently Asked Questions

1. How often can a single patient be screened for study eligibility?
There is no limit to the number of times a patient may be screened since eligibility criteria are inherently dynamic. i.e.) a decreasing vasopressor dose may be increased due to changes in the patient's condition. That same patient can be screened again when the vasopressor dose decreases again.

2. Our ICU has a standard Q8H medication administration time of 0600/1400/2200 hrs. Can the first dose of IP be delayed and given at those times?
The IP must be given at the time the patient is randomized to study treatment and then every 8 hours after that. If administration is delayed the patient may no longer be eligible by the time they get their first dose of study drug.

3. If IV vasopressors are restarted less than 24 hours after discontinuation how should the IP be administered?
The study IP must be given for a total of 24 hours after vasopressors are discontinued. If vasopressors are restarted in less than 24 hours, continue giving the study IP until a full 24 hour period without IV vasopressor therapy occurs.

4. Should the participant continue to receive the study IP if they are discharged to the ward less than 24 hours after discontinuation of IV vasopressors?
Yes, the IP follows the patient to the ward so that all doses are given to complete the 24 hour period of administration after discontinuation of IV vasopressors.

5. What 24 hour period should be used for daily data entry?
Day 1 data entry starts at the time of first IP administration and ends at 0659 the following day. The following daily entries will start at 0700 and end at 0659.

Participating sites

- Grey Nuns Hospital ICU
- Misericordia Hospital ICU
- University of Alberta Hospital GSICU

Upcoming sites in 2023

- Sturgeon Hospital ICU
- Rockyview Hospital ICU

Study Recruitment



Site	Total enrolled
Grey Nuns Hospital ICU	17
Misericordia Hospital ICU	7
U of A Hospital GSICU	4

For more information contact:
Oleksa Rewa, Principle Investigator
rewa@ualberta.ca
Dawn Opgenorth, Project Manager
dawno@ualberta.ca